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A lot of prescription medicines have become switch over-the-counter (OTC) medicines. However, additives in brand-name drugs,
generic drugs, and switch OTC drugs differ; therefore, the feelings associated with the use of these medicines vary for patients.The
aim of this study was to compare the physicochemical properties and the feeling of use (assuming skin as an index of usability) of
acyclovir (ACV) ointments. Five ACV ointments were used: ACV-A, a brand-name drug, ACV-B and ACV-C, generic drugs, and
ACV-D and ACV-E, switch OTC drugs. The physicochemical properties were evaluated by determining the content uniformity,
water content, flattening, viscosity and viscoelasticity, and near-infrared (NIR) absorption spectroscopy. Skin frictionwasmeasured
to evaluate the feeling associated with use. Results of the content uniformity test indicated that the ACV content was uniform, and
equivalence was observed. Measurement of moisture content indicated that this parameter differed in each ointment preparation.
The yield value, which was calculated by measuring flattening, was 4416.7 dyne/cm2 for ACV-A, 1175.7 dyne/cm2 for ACV-B, 2114.9
dyne/cm2 for ACV-C, 4234.5 dyne/cm2 for ACV-D, and 3620.7 dyne/cm2 for ACV-E. Measurement of viscosity and viscoelasticity
revealed that viscosity increased with time and the viscoelasticity of each ointment. The second derivative of the NIR spectrum
revealed that ACV-B and ACV-C had a wider spectrum of absorption than the other ointments. ACV-B had lesser friction than
other ointments. These findings suggest that differences in the type and content of additives (macrogol) result in differences in the
physicochemical properties of individual ointments.
1. Introduction
A lot of prescription medicines become switch OTC drugs,
making it possible to purchase these medicines without
prescription with instructions from a pharmacist for self-
medication [1, 2]. Famotidine, a gastric acid secretion
inhibitor, and indomethacin, an anti-inflammatory drug, are
switch OTC drugs for internal medicine, and terbinafine
hydrochloride, an antifungal drug, and vidarabine, an antivi-
ral drug, are switch OTC drugs for external medicine. These
medicines require pharmacotherapy for patient care through
a counter service or a recommendation from a pharmacist
to receive a medical examination [3]. Generic drugs can also
be prescription drugs and are prescribed as needed by the
patient [4]. However, the additives contained in brand-name
drugs, generic drugs, and switch OTC drugs differ; therefore,
patient experience of these drugs varies.
For example, physicochemical properties of vidarabine
were evaluated using brand-name drugs, generic drugs, and
switch OTC drugs, and differences in the viscosity of each
formulation due to differences in additives in the formulation
were reported [5]. Thus, the additives in brand-name drugs,
generic drugs, and switch OTC drugs differ and the feelings
associatedwith the use of different drug formulationsmust be
considered. Thus, pharmacists can advise on self-medication
by providing instructions to patients through an understand-
ing of the physicochemical properties of each formulation.
However, currently, a few reports have compared the physico-
chemical characteristics of brand-name drugs, generic drugs,
and switch OTC drugs.
Acyclovir (ACV) is a commonly used guanine analog
antiviral drug. It assumes its active form when phosphory-
lated in infected cells and subsequently prevents viral growth
[6, 7]. ACV is used for the prevention and treatment of
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Table 1: Additive of ACV ointment each formulation.
Brand name Lot number Serial number Additive
Zovirax Ointment 5% 3E7F ACV-A Macrogol 300, macrogol 1500
Acyclovir Ointment 5% “TEVA” CAO11 ACV-B Macrogol 300, macrogol 400, macrogol 4000
Acyclovir Ointment 5% “TOWA” A125 ACV-C Macrogol 400, macrogol 4000, pH adjuster
Activir UW3M ACV-D Macrogol
Hifuru AC Y503 ACV-E Macrogol
herpes simplex virus I (cold sores) and herpes simplex virus
II (genital herpes) infections. ACV is used as an internal
medicine, ointment, and cream. Also, these ACV formula-
tions are available as both brand-name and generic drugs.
Differences in the viscosity and viscoelasticity of brand-name
and generic ACV creams have been previously reported
[8]. Recently, switch OTC drugs for ACV ointments, which
require pharmacist guidance, have been used.
Previously, these ACV creams have reported on the
viscosity and incompatibility of original drugs and generic
products [8]. However, in this study, ACV ointment was
used to evaluate physical properties of OTC drugs as well
as prescription drugs (original drugs and generic products).
In order to predict an indication of usability in clinical,
performing the evaluation due to friction meter is believed
to play a role in providing information to healthcare pro-
fessionals and patients. In this study, the physicochemical
properties of ACV formulations were examined: Zovirax
Ointment 5%, a brand-name drug, Acyclovir Ointment
5% “TEVA,” Aciclovir Ointment 5% “TOWA,” a generic
drug, and Activir and Hifuru AC, switch OTC drugs.
The major additive contained in the brand-name, generic,
and switch OTC ACV ointments is macrogol. It has been
reported that the viscosity of polyethylene glycol, a macrogol,
varies depending on the average molecular weight and that
differences in the feelings associated with the use of the
preparation vary when polyethylene glycol is used as an
additive [9]. Therefore, differences in the average molecular
weight of macrogol were assessed, and the viscosity and
viscoelasticity of each ointment were evaluated. Additionally,
the skin friction of each ointment was measured, and the
feeling of use on the skin was evaluated. Furthermore, to
investigate the molecular behavior of the additive in each
formulation, the near-infrared (NIR) absorption spectrum
was measured. It would be considered to become an item
in visualization information of each ointment difference, so
mapping by main analysis statistical analysis was evaluated.
2. Materials and Methods
2.1. Materials. Commercial formulations of ACV ointments
were purchased. The brand-name ointment was Zovirax
Ointment 5% (GlaxoSmithKlineCo., Ltd.); generic ointments
were Acyclovir Ointment 5% “TEVA” (Teva Takeda Pharma
Ltd.) and Acyclovir Ointment 5% “TOWA” (Towa Phar-
maceutical Co., Ltd.); and OTC ointments were Activir
(GlaxoSmithKline ConsumerHealthcare JapanCo., Ltd.) and
HifuruAC (BankyoPharmaceutical Co., Ltd.).Theproperties
and additives of each formulation are shown in Table 1.
ACV crystal was purchased from Tokyo Kasei Co., Ltd.
Other reagents were of special commercial grade (Wako Pure
Chemical Industries Co., Ltd.).
2.2. Methods
2.2.1. Content Uniformity Test. For the assay, approximately
100 mg of each ointment was weighed; 12.5 mL of diluted
sodium hydroxide solution and 37.5 mL of distilled water
were added and dissolved. Then, 0.1 mol/L hydrochloric acid
solution was added to 7.5 mL of each ointment solution to
make 100 mL and test solutions were prepared. Approxi-
mately 10mg of ACVwas weighed; diluted sodiumhydroxide
solution was then added to reach 10 mL. Then, 7.5 mL of
diluted sodium hydroxide solution was added to the ACV
solution, and distilled water was added to make 50 mL.
Hydrochloric acid solution (0.1 mol/L) was added to reach
100 mL and a standard solution was prepared. Measurements
were made using a UV-vis recording spectrophotometer
(Shimadzu: UV-2500PC). Absorbance of test and standard
solutions was measured at a wavelength of 255 nm using 0.1
mol/L hydrochloric acid as a control.
The amount of each ACV ointment was calculated using
the following equation:
Amount of ACV (mg) =WS ∗ AT
AS
∗
1
2
(1)
where WS is weighed amount of ACV standard product
converted into dehydrate (mg), AT is absorbance of test
solution, and AS is absorbance of standard solution.
2.2.2. Measurement of Water Content. Water content was
measured using a Karl-Fisher moisture content meter (Kyoto
Electronics Manufacturing Co., Ltd.: MKV-710M). KEM
AQUATR-3 (Kyoto ElectronicsManufacturingCo., Ltd.) was
used as the titrant and KEM AQUA FAT (Kyoto Electronics
Manufacturing Co., Ltd.) served as the dehydrated solvent.
The water content in 0.03 g of each sample was measured
three times at 25∘C.
2.2.3. Measurement of Flattening. Spreadability was mea-
sured using a spread meter (Rigo) with a measuring temper-
ature of 25∘C. Spread diameter was measured after 5, 10, 60,
120, 180, 240, 300, 360, 600, and 900 s.
The yield value was calculated from the following formula
using the spread diameter after 180 s:
F = 47040 ∗ G ∗ V
𝜋2
∗ D5 (2)
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Table 2: Content uniformity of ACV ointments.
Formulation Uniformity (mean ± SD)
ACV-A 102.1 ± 2.0
ACV-B 100.8 ± 1.8
ACV-C 100.0 ± 1.4
ACV-D 103.1 ± 0.3
ACV-E 101.8 ± 0.8
Nonsignificant (n=3).
where F is yield value (dyne/cm2), G is glass plate weight
(115.5g), V is sample size (cm3), andD is diameter (mm)when
sample spreading stopped.
2.2.4. Viscosity and Viscoelasticity. Dynamic viscosity was
measured using a type-E rotational viscometer (Toki Sangyo:
TVE-20H). The dynamic viscosity of 0.02 mL of each oint-
ment was measured for 553 s at 25∘C using the viscometer
with a 3∘× R9.7 cone rotor. Measurements were made at
a shear rate of 0.01-0.08 󳨀→ 0.08 -0.01 s−1 (0.01 s−1: 60 s,
the other shear rate: 30 s). The viscosity was measured at a
shear rate of 0.08 s−1 for 276 s. Viscoelasticity measured the
recovery and stress at a shear rate of 1 s before the shear rate
changes. The viscoelasticity of each ointment was measured
three times under the same conditions.
2.2.5. Near-Infrared Absorption Spectroscopy. NIR absorp-
tion spectra were recorded using a Fourier-transform near-
infrared analyzer (Buchi NIRFlex N-500). Spectroscopy was
performed at a wavelength of 1000-2500 nm and a wavenum-
ber of 10,000-4000 cm−1, and spectra were recorded for 8 s at
25∘C. Each ointment was placed in a sample cup, and the NIR
absorption spectra were measured at 1 nm intervals.
2.2.6. Skin FrictionMeasurement. The skin friction produced
by each ointment was measured using the Frictiometer
(Courage + Khazaka Electronic GmbH: FR 700). A 0.1 g
sample of each ointment was applied to artificial skin, and
skin friction at 25∘C was measured by agitation for 20 s at 25
rpm.
2.2.7. Statistical Analysis. Statistical analysis was performed
using Tukey’s test, with p<0.05 considered to indicate a
significant difference.
3. Results and Discussion
3.1. Content Uniformity Test. Auniformity of content test was
conducted to assess the equivalence of ACV content in each
ointment (Table 2). The percentage ACV in ACV-A, ACV-B,
ACV-C, ACV-D, andACV-Ewas 102.1 ± 2.0, 100.8 ± 1.8, 100.0
± 1.4, 103.1 ± 0.310, and 101.8 ± 0.8%. Tukey’s test revealed
no significant difference in the uniformity of content in the
five ointments. Thus, the contents of ACV in ACV-A, ACV-
B, ACV-C, ACV-D, and ACV-E were considered uniform.
3.2. Measurement of Moisture Content. Themoisture content
of each formulation was determined. The results indicated
Table 3: Spreadability of ACV ointments at 25∘C.
Formulation Spreadability (mean ± SD)
ACV-A 22.9 ± 0.1
ACV-B 29.8 ± 0.2
ACV-C 26.5 ± 0.2
ACV-D 23.1 ± 0.3
ACV-E 23.8 ± 0.3
Value of the spreadability after 180 seconds (n=3).
that ACV-A had a moisture content of 1.36 ± 0.27%, ACV-
B had a moisture content of 3.22 ± 0.75%, ACV-C had a
moisture content of 3.52 ± 0.43%, ACV-D had a moisture
content of 1.29 ± 0.19%, and ACV-E had a moisture content
of 4.56 ± 0.94%. This indicated that the moisture content in
each formulation differed.
3.3. Measurement of Flattening. The feeling associated with
the use of a semisolid preparation can be evaluated by
assessing extensibility and hardness, which are indexes of
spreadability and yield value, using a spread meter [10].
Therefore, the spreadability and yield value of each ointment
preparation were calculated using a spread meter, and the
physical properties were evaluated (Table 3 and Figures 1
and 2). The spreadability was evaluated by comparing the
diameters at 180 s when the spreading of each ointment
preparation was stable. The diameter of the ointment spread
in 180 s was 22.9 mm for ACV-A, 29.8 mm for ACV-B,
26.5 mm for ACV-C, 23.1 mm for ACV-D, and 23.8 mm
for ACV-E. From this, the spread of ACV-B was found
to cover a wider diameter compared to that of the other
ointments. A similar spread of about 23 mm in diameter
was found for ACV-A, ACV-D, and ACV-E. Next, the yield
values of ACV-A, ACV-B, ACV-C, ACV-D, and ACV-E,
which are indexes of hardness, were calculated. The yield
value was 4416.7 dyne/cm2 for ACV-A, 1175.7 dyne/cm2 for
ACV-B, 2114.9 dyne/cm2 for ACV-C, 4234.5 dyne/cm2 for
ACV-D, and 3620.7 dyne/cm2 for ACV-E. The spreadability
and yield value indicated that ACV ointments are soft and
extensible preparations in the order of ACV-B > ACV-
C > ACV-E > ACV-D > ACV-A. In addition, the spread
diameters of ACV-A and ACV-D were similar, and ACV-A
and ACV-D exhibited hardness and extensibility compared
with other ointments. The extensibility of ointment is due
to the additives contained in the preparation [11]. Thus, the
differences in spreadability and yield value of each ointment
affected themolecular weight andmacrogol content, which is
an additive contained in each ointment.
3.4. Measurement of Viscosity and Viscoelasticity. Viscosity
was measured to evaluate the viscosity characteristics of each
ointment (Figure 3). After 276 s, ACV-A had a viscosity
of 1428.8 Pa⋅s, ACV-B had a viscosity of 1092.8 Pa⋅s, ACV-
C had a viscosity of 1323.1 Pa⋅s, ACV-D had a viscosity
of 1450.0 Pa⋅s, and ACV-E had a viscosity of 1588.6 Pa⋅s.
There was a small increase in the viscosity of ACV-B over
time compared with the other ointments. Thus, the ACV-
B formulation undergoes little change in internal structure
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Figure 1: Average diameter of ACV ointments in Logarithm time.
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Figure 2: Yield value of ACV ointments at 25∘C. Value of the
spreadability after 180 seconds (mean ± SD, n=3). Tukey’s test was
given for official approval (p<0.05). ∗ indicates that significant
differences were seen between ACV-A and ACV-B and between
ACV-A and ACV-C (p<0.05 for each). ∗∗ indicates that significant
differences were seen between ACV-B and ACV-C, between ACV-
B and ACV-D, and between ACV-B and ACV-E (p<0.05 for each).
∗∗∗ indicates that significant differences were seen betweenACV-C
and ACV-D and between ACV-C and ACV-E (p<0.05 for each).
when subjected to shear stress. Conversely, the viscosity of
ACV-E changed markedly over time compared with that
of the other ointments. In addition, the viscosity of ACV-
A, ACV-C, and ACV-D similarly increased with time. The
differing changes in viscosity over time between ointments
did not confirm the results obtained for moisture content
and spreadability. As such, the varying changes in viscosity
with time may have been due to differences in the molecular
weight and content of the additive macrogol.
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Figure 3: Viscosity curves of ACV ointments at 25∘C.
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Figure 4: Shear stress versus shear speed curves of ACV ointments.
The viscosity of each ointment preparation differed;
therefore, the viscoelasticity of each ointment preparation
was evaluated (Figure 4). The shear stress of ACV-B was low,
while that of ACV-E was high compared with the other oint-
ments. In addition, the shear stresses of ACV-A, ACV-C, and
ACV-D were similar. These results indicate that ACV-B has
properties of softness compared with the other formulations.
Conversely, ACV-E has properties of strength compared with
the other formulations. This was correlated with viscosity.
The rheogram observed with an increase in shear rate
differed from that observed with a decrease in shear rate, and
a hysteresis loop was observed for all ointment formulations.
The presence of a hysteresis loop indicates that time is needed
to recover the internal structure, which changed when the
shear rate increased [12]. In addition, it is possible to evaluate
the thixotropy, that is, the strength of the internal structure by
the difference in the area of the hysteresis loop of flow curves
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Figure 5: Viscoelasticity curves of each ACV ointment at repeated measurements. (a) ACV-A, (b) ACV-B, (c) ACV-C, (d) ACV-D, and (e)
ACV-E.
when the shear rate is up and down.The area of the hysteresis
loop of ACV-B was small, and the area of the hysteresis loop
of ACV-Ewas large comparedwith that of the other ointment
preparations. From the results of the viscosity measurement,
the stickiness was confirmed by adding the shear stress.
Thus, from the results of viscosity and viscoelasticity, ACV-
B was inferred to undergo less change in its internal structure
when subjected shear stress and to have properties of softness
compared with the other ointments. Conversely, the internal
structure of ACV-E was easily changed by shear stress, with a
harder formulation compared with the other ointments.
Next, repeatedmeasurements were performed to evaluate
changes in the robustness, viscosity, and viscoelasticity of
each ointment (Figure 5). When ACV-E was subjected to
repeated shear stress, the shear stress decreased in the third
run compared with the first and second runs. Thus, the
internal structure of ACV-E may be susceptible to disruption
whenACV-E is subjected to repeated shear stress. In addition,
the shear stress of ACV-B and ACV-C underwent minimal
change even under repeated shear stress. Thus, ACV-B and
ACV-C were considered to possess viscoelasticity, and the
internal structure of ACV-B and ACV-C could be main-
tained, even under shear stress. Additionally, the shear stress
of ACV-A and ACV-D increased in the third run compared
to that in the first and second runs. Thus, when ACV-A and
ACV-Dwere subjected to repeated shear stress, there was less
disruption to their internal structures.
The results obtained for viscosity and viscoelasticity
differed from those obtained for spreadability and yield value.
This suggests that there are differences in the extensibility
and change in the internal structure of each ointment.
The viscosity and viscoelasticity of cream preparations have
been reported to vary depending on the proportion of oil
contained in cream [13]. Therefore, in this study, differences
in viscosity and viscoelasticity among the ointment prepa-
rations were due to differences in moisture content and the
molecular weight and content of macrogol. In addition, from
the results obtained thus far, ACV-A and ACV-D appear to
have similar properties. Thus, macrogol, which is contained
by ACV-A and ACV-D as an additive, accounted for their
similar molecular weight and content.
3.5. Near-Infrared Absorption Spectroscopy. NIR absorption
spectra were recorded to verify differences in the water or
oil content of each formulation (Figure 6). The absorption
spectrum of the olefin group (-CH
2
) in the oleaginous base
was observed at 4300 and 5800 cm−1, and that of the hydroxyl
group (-OH) caused by moisture was observed around 5200
cm−1.The current study evaluated the oil andwater content of
each formulation focusing on these spectra [14, 15]. The sec-
ond derivative of the NIR absorption spectrum revealed that
ACV-B and ACV-C possessed a wider absorption spectrum
than the other ointments due to the olefin group (Figure 6(a)).
Moreover, ACV-E possessed a larger spectrum than the other
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Figure 6: Near-infrared absorption spectra of ACV ointments, observed to 4000-10000 cm−1. (a) 2nd differential near-infrared absorption
spectra of ACV ointments, observed to 5700-5950 cm−1. (b) 2nd differential near-infrared absorption spectra of ACV ointments, observed
to 5100-5300 cm−1.
ointments due to the hydroxyl group (Figure 6(b)). From
these results, differences in oleaginous base and moisture
content of each formulation were clarified.
To evaluate differences in the principal component of
each formulation, a principal component analysis was per-
formed (Figure 7) [16]. In principal component 1 (PC1), ACV-
A and ACV-D were similar, ACV-B and ACV-C were similar,
and ACV-E differed from other ointments. In principal
component 2 (PC2), ACV-A and ACV-D were similar, ACV-
B and ACV-C were similar, and ACV-E differed from other
ointments. Moisture content analysis and NIR absorption
spectroscopy suggested that PC1 reflected differences in the
water content of each formulation. PC2 differed between the
five formulations. PC2 was considered to reflect differences
in the molecular weight and the content of oleaginous bases
and macrogol in ACV ointments. These results indicate that
ointment spreadability is due to the moisture content of
each formulation and the molecular weight and content
of macrogol contained in each ointment. In addition, the
viscosity and viscoelasticity of ointments were due to the
molecular weight and content of macrogol contained in each
ointment. Generally, macrogol is known to have different
properties depending on the molecular weight of macrogol.
For example, macrogol 400 is liquid and macrogol 4000 is
solid at normal temperature, and the viscosity of macro-
gol 400 is lower compared with the viscosity of macrogol
4000. Therefore, the results of spreadability, viscosity, and
viscoelasticity are considered due to the difference of the
molecular weight of macrogol and each macrogol content
of each ointment. Comparing the additives contained in
each ointment, ACV-B and ACV-C contain macrogol 4000.
However, these results indicated that ACV-B and ACV-C
were soft and extensible preparations compared to other oint-
ments. Therefore, the properties of ACV-B and ACV-C were
considered due to the difference of each macrogol content.
In addition, the difference of the formulation process of each
ointment was also considered to contribute to the properties
of the ointment preparation. Furthermore, the molecular
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Figure 8: Skin friction of ACV ointments, respectively (n=5).
weight of macrogol in ACV-D has not been reported.
However, the moisture content, spreadability, viscosity, and
viscoelasticity of ACV-D were similar to those of ACV-A;
therefore, the molecular weight of macrogol contained in
ACV-D was presumed to be 300 and 1500, which was the
molecular weight of macrogol contained in ACV-A. The
molecular weight of macrogol in ACV-E as an additive has
not been reported. However, from the viscosity measurement
and the second derivative of NIR absorption spectra, the
molecular weight of macrogol with ACV-E was inferred
to be lower than that with ACV-B and ACV-C. However,
generally, the viscosity of high-molecular-weight macrogol is
higher than the viscosity of low-molecular-weight macrogol.
Therefore, the properties of ACV-E were considered due to
the difference of each macrogol content and the production
process of each ointment.
3.6. Skin FrictionMeasurement. TheFrictiometer was used to
measure friction in order to evaluate the feeling of the creams
when applied to the skin (Figure 8). This was also used to
evaluate the feeling of cosmetics on the skin [17]. After 15 s,
ACV-A had a friction measurement of 356.5 N, ACV-B had
121.6 N, ACV-C had 162.4 N, ACV-D had 349.7 N, and ACV-
E had 187.5 N. The magnitude of the friction force followed
the same pattern as the yield value calculated with a spread
meter. The force of friction was inversely correlated with the
spreadability and slipperiness of a semisolid preparation and
was correlated with the stickiness of the preparation. Thus,
ACV-Bwas inferred to be not sticky and to spread easilywhen
applied to human skin compared with the other ointments.
4. Conclusion
A uniformity of content test revealed that ACV-A, ACV-
B, ACV-C, ACV-D, and ACV-E possess equivalent ACV
contents. Evaluation of the properties of each ointment
revealed the physicochemical properties of ACV-A, ACV-B,
ACV-C, ACV-D, and ACV-E. A skin friction test revealed
differences in the properties of ACV-A, ACV-B, ACV-C,
ACV-D, and ACV-E.This study investigated the properties of
different ACV formulations in a model scenario involving a
brand-name ointment, a generic ointment, and a switch OTC
ointment. In the future, pharmacists will need to investigate
the properties of OTC formulations. This will help maintain
the health of the community and encourage appropriate self-
medication.
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